[A22-49] Doravirine/lamivudine/ tenofovir disoproxil (HIV infection) – Benefit assessment according to §35a Social Code Book V
Last updated 01.08.2022
Project no.:
A22-49
Commission:
Commission awarded on 29.04.2022 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Immune system and infections
Indication:
Pretreated adolescents infected with HIV-1
Result of dossier assessment:
Added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Accompanying information| Project no. | Title | Status |
|---|---|---|
| A19-05 | Doravirine/lamivudine/tenofovir disoproxil (HIV infection) - Benefit assessment according to §35a Social Code Book V | Commission completed |